Dr Josep Maria Ribera, head of the Acute Lymphoblastic Leukaemia laboratory at the Josep Carreras Leukaemia Research Institute, has been awarded the prestigious EHA Clinical Excellence Award 2026. This distinction recognises his outstanding scientific and clinical contributions to the clinical haematology, his leadership in the international blood cancer research community and his long-lasting commitment to training and mentoring the new generations of haematologists.

 A cancer researcher at the University of Houston is reporting what makes malignant soft tissue cancer grow in children, identifying key mechanisms and molecular targets to prevent tumor progression in patients in future therapies of the fatal rhabdomyosarcoma.

New Memorial Sloan Kettering Cancer Center (MSK) research shows the largely overlooked "tail" region of mRNAs helps ensure key regulatory proteins get folded correctly — a fundamentally new understanding of their role.

Three commercially available radiology AI systems have shown the potential to flag early signs of breast cancer up to 6 years before a diagnosis, according to a new study.

Chemical changes added to proteins after they are made are emerging as a powerful way to understand how cancers grow, spread, evade immunity, and resist treatment. 

Bladder cancer remains difficult to treat once it becomes advanced, recurrent, or resistant to conventional therapies. 

New research found that extreme heat is already influencing how people with cancer manage daily life, access care, and make treatment-related decisions. The study highlights the need to integrate environmental risk into cancer care planning, from clinical conversations and appointment planning to caregiver guidance and community support.

Nanjing University researchers report a breakthrough siRNA delivery strategy that transforms the liver into a "biopharmaceutical factory" for targeted cancer therapy. The team developed an In Vivo Self-Assembled (IVSA) system that uses intravenously injected plasmid DNA to program hepatocytes to produce and package EGFR-targeting siRNA into GE11-tagged small extracellular vesicles. These "biomissiles" selectively deliver therapeutic siRNA to EGFR-positive tumors, overcoming the long-standing siRNA delivery challenge without complex in vitro encapsulation. The system demonstrated potent efficacy across EGFR-mutant lung cancer, gastric cancer, and breast cancer models, outperforming traditional targeted drugs while showing minimal off-target toxicity. This plug-and-play platform represents a paradigm shift from conventional drug manufacturing to in vivo biopharmaceutical production, offering a modular, cost-effective approach for personalized cancer gene therapy.